Vol. 5 No. 5S (2011)

Published: 2011-12-15

Editorial

Resistance and/or intolerance: one more chance!

Luigia Luciano

3-6
- PDF

Case report

Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib

Sabina Russo, Giuseppa Penna, Arianna D’Angelo, Alessandro Allegra, Andrea Alonci, Caterina Musolino

7-14
- PDF
Efficacy of nilotinib in a patient in non-optimal response after imatinib treatment but in reduced compliance to the new drug

Francesca Sassolini

15-19
- PDF
Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain

Maria Iovine, Giuseppe Monaco, Mario Troiano, Antonio Abbadessa

21-25
- PDF
Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib

Emilio Usala

27-30
- PDF